<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149642</url>
  </required_header>
  <id_info>
    <org_study_id>IMPATOX</org_study_id>
    <secondary_id>VA2009/13</secondary_id>
    <nct_id>NCT01149642</nct_id>
  </id_info>
  <brief_title>Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer</brief_title>
  <acronym>IMPATOX</acronym>
  <official_title>Phase III Multicenter, Randomised and Double-blind Study Comparing an Oral Immunomodulatory Solution Versus a Placebo in Preventing Severe Acute Mucositis in Head and Neck Cancer Patients Treated Surgically and Concomitantly With Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GORTEC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <brief_summary>
    <textblock>
      This randomised, double-blind study will compare an oral immunomodulatory solution to a&#xD;
      placebo for the prevention of acute severe mucositis in head and neck cancer patients treated&#xD;
      surgically and concomitantly with radiochemotherapy. The investigators expect a decrease of&#xD;
      25% of severe acute mucositis in experimental arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of grade 3 and 4 acute mucosal toxicity</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>tolerance of treatment with the CTCAE (Common Terminology Criteria for Adverse Events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compliance to the oral immunomodulating formula</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall quality of life (EORTC QLQ-C30 Questionnaire)</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival rates</measure>
    <time_frame>1, 2 and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rates</measure>
    <time_frame>1, 2 and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Severe Acute Mucositis</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Oral immunomodulatory solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The oral supplement is a 74g sachet containing 302 kcal and 16.7g proteins as well as immunonutrients such as L-Arginine, ARN and omega-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Impact</intervention_name>
    <description>The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.&#xD;
This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes.</description>
    <arm_group_label>Oral immunomodulatory solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Epidermal carcinoma proven histologically of the sphere ORL (all locations except&#xD;
             nasopharynx).&#xD;
&#xD;
          -  Patients with tumours of the oral cavity, the oropharynx, the hypopharynx and the&#xD;
             larynx treated initially by surgery and eligible for post-operative radio-&#xD;
             chemotherapy concomitantly.&#xD;
&#xD;
        NB. The patients with tumours of the larynx or hypopharynx are eligible if the radiotherapy&#xD;
        to the oropharyngeal mucosa will be at least 54 Gy and the mucositis can be visualised&#xD;
        without the use of instruments.&#xD;
&#xD;
          -  Radio-chemotherapy to be given postoperatively.&#xD;
&#xD;
          -  Maximum delay of 8 weeks between the operative date and the planned starting date of&#xD;
             radio-chemotherapy.&#xD;
&#xD;
          -  Performance status (grade OMS): 0, 1, 2&#xD;
&#xD;
          -  Nutritional Risk Index ≥ 83.5&#xD;
&#xD;
          -  No mucositis.&#xD;
&#xD;
          -  Age: 18-75 years&#xD;
&#xD;
          -  Life expectancy ≥ 3 months.&#xD;
&#xD;
          -  Informed consent obtained from the patient.&#xD;
&#xD;
          -  Affiliation with a social security system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumour of nasopharynx&#xD;
&#xD;
          -  Mucositis&#xD;
&#xD;
          -  Severe sepsis&#xD;
&#xD;
          -  Treatment by immunomodulators in the month preceding inclusion&#xD;
&#xD;
          -  ATCD allergy to the components of Oral Impact.&#xD;
&#xD;
          -  Parenteral nutrition at inclusion&#xD;
&#xD;
          -  Usual contraindications to concomitant radio-chemotherapy&#xD;
&#xD;
          -  Patient already included in another therapeutic trial involving an experimental&#xD;
             molecule&#xD;
&#xD;
          -  Female pregnant or susceptible to being pregnant, or breast-feeding. Patient not using&#xD;
             appropriate contraceptive measures during the treatment&#xD;
&#xD;
          -  Persons deprived of liberty or under guardianship&#xD;
&#xD;
          -  Patients unable to commit to the trial schedule for geographical, social or&#xD;
             psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier - Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

